ZIOP - Stephens sees 48% upside in Cerus in premarket analyst action August, 23 2019 07:17 AM ZIOPHARM Oncology Inc Repligen (NASDAQ:RGEN) resumed with Overweight rating and $110 (19% upside) price target at Stephens.More news on: Repligen Corporation, ZIOPHARM Oncology, Inc., Cerus Corporation, Healthcare stocks news, , Read more ...